The Anti-Fibrotic Effect of Cold Atmospheric Plasma on Localized Scleroderma In Vitro and In Vivo

Cold Atmospheric Plasma (CAP) has shown promising results in the treatment of various skin diseases. The therapeutic effect of CAP on localized scleroderma (LS), however, has not yet been evaluated. We investigated the effects of CAP on LS by comparing human normal fibroblasts (hNF), human TGF-β-act...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Stephanie Arndt, Petra Unger, Anja-Katrin Bosserhoff, Mark Berneburg, Sigrid Karrer
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	cold atmospheric plasma localized scleroderma anti-fibrosis bleomycin-induced fibrosis Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/0396ff122f604ca8bcd1d7b46c426ad9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0396ff122f604ca8bcd1d7b46c426ad9
record_format	dspace
spelling	oai:doaj.org-article:0396ff122f604ca8bcd1d7b46c426ad92021-11-25T16:48:50ZThe Anti-Fibrotic Effect of Cold Atmospheric Plasma on Localized Scleroderma In Vitro and In Vivo10.3390/biomedicines91115452227-9059https://doaj.org/article/0396ff122f604ca8bcd1d7b46c426ad92021-10-01T00:00:00Zhttps://www.mdpi.com/2227-9059/9/11/1545https://doaj.org/toc/2227-9059Cold Atmospheric Plasma (CAP) has shown promising results in the treatment of various skin diseases. The therapeutic effect of CAP on localized scleroderma (LS), however, has not yet been evaluated. We investigated the effects of CAP on LS by comparing human normal fibroblasts (hNF), human TGF-β-activated fibroblasts (hAF), and human localized scleroderma-derived fibroblasts (hLSF) after direct CAP treatment, co-cultured with plasma-treated human epidermal keratinocytes (hEK) and with an experimental murine model of scleroderma. In hAF and hLSF, 2 min CAP treatment with the MicroPlaSterβ<sup>®</sup> plasma torch did not affect pro-fibrotic gene expression of alpha smooth muscle actin, fibroblast activating protein, and collagen type I, however, it promoted re-expression of matrix metalloproteinase 1. Functionally, CAP treatment reduced cell migration and stress fiber formation in hAF and hLSF. The relevance of CAP treatment was confirmed in an in vivo model of bleomycin-induced dermal fibrosis. In this model, CAP-treated mice showed significantly reduced dermal thickness and collagen deposition as well as a decrease in both alpha smooth muscle actin-positive myofibroblasts and CD68-positive macrophages in the affected skin in comparison to untreated fibrotic tissue. In conclusion, this study provides the first evidence for the successful use of CAP for treating LS and may be the basis for clinical trials including patients with LS.Stephanie ArndtPetra UngerAnja-Katrin BosserhoffMark BerneburgSigrid KarrerMDPI AGarticlecold atmospheric plasmalocalized sclerodermaanti-fibrosisbleomycin-induced fibrosisBiology (General)QH301-705.5ENBiomedicines, Vol 9, Iss 1545, p 1545 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	cold atmospheric plasma localized scleroderma anti-fibrosis bleomycin-induced fibrosis Biology (General) QH301-705.5
spellingShingle	cold atmospheric plasma localized scleroderma anti-fibrosis bleomycin-induced fibrosis Biology (General) QH301-705.5 Stephanie Arndt Petra Unger Anja-Katrin Bosserhoff Mark Berneburg Sigrid Karrer The Anti-Fibrotic Effect of Cold Atmospheric Plasma on Localized Scleroderma In Vitro and In Vivo
description	Cold Atmospheric Plasma (CAP) has shown promising results in the treatment of various skin diseases. The therapeutic effect of CAP on localized scleroderma (LS), however, has not yet been evaluated. We investigated the effects of CAP on LS by comparing human normal fibroblasts (hNF), human TGF-β-activated fibroblasts (hAF), and human localized scleroderma-derived fibroblasts (hLSF) after direct CAP treatment, co-cultured with plasma-treated human epidermal keratinocytes (hEK) and with an experimental murine model of scleroderma. In hAF and hLSF, 2 min CAP treatment with the MicroPlaSterβ<sup>®</sup> plasma torch did not affect pro-fibrotic gene expression of alpha smooth muscle actin, fibroblast activating protein, and collagen type I, however, it promoted re-expression of matrix metalloproteinase 1. Functionally, CAP treatment reduced cell migration and stress fiber formation in hAF and hLSF. The relevance of CAP treatment was confirmed in an in vivo model of bleomycin-induced dermal fibrosis. In this model, CAP-treated mice showed significantly reduced dermal thickness and collagen deposition as well as a decrease in both alpha smooth muscle actin-positive myofibroblasts and CD68-positive macrophages in the affected skin in comparison to untreated fibrotic tissue. In conclusion, this study provides the first evidence for the successful use of CAP for treating LS and may be the basis for clinical trials including patients with LS.
format	article
author	Stephanie Arndt Petra Unger Anja-Katrin Bosserhoff Mark Berneburg Sigrid Karrer
author_facet	Stephanie Arndt Petra Unger Anja-Katrin Bosserhoff Mark Berneburg Sigrid Karrer
author_sort	Stephanie Arndt
title	The Anti-Fibrotic Effect of Cold Atmospheric Plasma on Localized Scleroderma In Vitro and In Vivo
title_short	The Anti-Fibrotic Effect of Cold Atmospheric Plasma on Localized Scleroderma In Vitro and In Vivo
title_full	The Anti-Fibrotic Effect of Cold Atmospheric Plasma on Localized Scleroderma In Vitro and In Vivo
title_fullStr	The Anti-Fibrotic Effect of Cold Atmospheric Plasma on Localized Scleroderma In Vitro and In Vivo
title_full_unstemmed	The Anti-Fibrotic Effect of Cold Atmospheric Plasma on Localized Scleroderma In Vitro and In Vivo
title_sort	anti-fibrotic effect of cold atmospheric plasma on localized scleroderma in vitro and in vivo
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/0396ff122f604ca8bcd1d7b46c426ad9
work_keys_str_mv	AT stephaniearndt theantifibroticeffectofcoldatmosphericplasmaonlocalizedsclerodermainvitroandinvivo AT petraunger theantifibroticeffectofcoldatmosphericplasmaonlocalizedsclerodermainvitroandinvivo AT anjakatrinbosserhoff theantifibroticeffectofcoldatmosphericplasmaonlocalizedsclerodermainvitroandinvivo AT markberneburg theantifibroticeffectofcoldatmosphericplasmaonlocalizedsclerodermainvitroandinvivo AT sigridkarrer theantifibroticeffectofcoldatmosphericplasmaonlocalizedsclerodermainvitroandinvivo AT stephaniearndt antifibroticeffectofcoldatmosphericplasmaonlocalizedsclerodermainvitroandinvivo AT petraunger antifibroticeffectofcoldatmosphericplasmaonlocalizedsclerodermainvitroandinvivo AT anjakatrinbosserhoff antifibroticeffectofcoldatmosphericplasmaonlocalizedsclerodermainvitroandinvivo AT markberneburg antifibroticeffectofcoldatmosphericplasmaonlocalizedsclerodermainvitroandinvivo AT sigridkarrer antifibroticeffectofcoldatmosphericplasmaonlocalizedsclerodermainvitroandinvivo
_version_	1718412936656977920

The Anti-Fibrotic Effect of Cold Atmospheric Plasma on Localized Scleroderma In Vitro and In Vivo

Ejemplares similares